Trial NCT04425629

View at ClinicalTrials.gov 
Org. Study IDs: R10933-10987-COV-2067
Secondary IDs: 2020-003690-21

Last trial update was posted on 2023-12-21

MeSH Interventions

Casirivimab and imdevimab drug combination

MeSH Conditions

COVID-19

Other Conditions


Stopping Reasons

Emerging SARS-CoV-2 variants impacting susceptibility to study drug

Limitations And Caveats

Nasal and saliva sample collection was discontinued early in the study because nasopharyngeal samples were determined to be more reliable for quantitative analysis, as such endpoints related to nasal or saliva samples were not analyzed. The Phase 1/2 SAP does not specify any analyses related to nasal and saliva samples collections

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID